Response to “Development and validation of the Frontal Fibrosing Alopecia Severity Score” - 10/11/18
Doi : 10.1016/j.jaad.2018.05.1262
Susan Holmes, BSc (Hons), MD, FRCP a, ⁎ 
, Matthew Harries, PhD, FRCP b, c, d, e
, Matthew Harries, PhD, FRCP b, c, d, e a Alan Lyell Centre for Dermatology, Queen Elizabeth University Hospital, Glasgow, Scotland
b The Dermatology Centre, Salford Royal National Health Service Foundation Trust, Salford, Greater Manchester, England
c Centre for Dermatology Research, University of Manchester, Manchester, England
d Manchester Academic Health Science Centre, Manchester, England
e National Institute for Health Research Manchester Biomedical Research Centre, Manchester, England
∗Correspondence to: Susan Holmes, BSc (Hons), MD, FRCP, Alan Lyell Centre for Dermatology, Queen Elizabeth University Hospital, 1345 Govan Rd, Glasgow G51 4TF, ScotlandAlan Lyell Centre for DermatologyQueen Elizabeth University Hospital1345 Govan RdGlasgowScotlandG51 4TF
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 79 - N° 6
P. e115-e116 - décembre 2018 Retour au numéro
Article précédent
- Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study’”
- Outi Varpuluoma, Laura Huilaja, Kaisa Tasanen
- Reply to: “Response to ‘Development and validation of the Frontal Fibrosing Alopecia Severity Score’”
- David Saceda-Corralo, Óscar M. Moreno-Arrones, Cristina Pindado-Ortega, Sergio Vañó-Galván
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?